This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Abbvie, Cerevel Therapeutics to file US antitrust paperwork within 10 days

( December 7, 2023, 14:26 GMT | Official Statement) -- MLex Summary: Abbvie and Cerevel Therapeutics are expected to file US antitrust paperwork within 10 days from their Dec. 7 merger agreement, according to a securities filing. The companies said that the UK Competition and Markets Authority may decide to formally investigate the merger and request the companies submit a merger notice; and the European Commission may also indicate that a member state of the European Union is making, or has made, a referral of the merger to the EC under Article 22 of the EU Merger Regulation, in which case the deal would also be reviewed by the European Commission.Extract....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login